Letters
The cancer label
Low risk cancer: recalibrate rather than just rename?
BMJ 2018; 363 doi: https://doi.org/10.1136/bmj.k4211 (Published 09 October 2018) Cite this as: BMJ 2018;363:k4211- Murali Varma, consultant histopathologist
- University Hospital of Wales, Cardiff CF14 4XW, UK
- varmam{at}cardiff.ac.uk
The controversy about renaming some low risk cancers1 is partly related to the perception of “benign” and “malignant” as biologically distinct conditions, when there is a continuum of increasing risk from benign to “good cancer” and “bad cancer.”2
The distinction between good and bad cancer is generally accepted to be arbitrary, with any risk of metastasis …
Log in
Log in using your username and password
Log in through your institution
Subscribe from £173 *
Subscribe and get access to all BMJ articles, and much more.
* For online subscription
Access this article for 1 day for:
£38 / $45 / €42 (excludes VAT)
You can download a PDF version for your personal record.